Journal of Neuromuscular Diseases - Volume 11, issue 1

Authors: Lochmüller, Hanns | Bönnemann, Carsten G.

Article Type: Editorial

DOI: 10.3233/JND-249000

Citation: Journal of Neuromuscular Diseases, vol. 11, no. 1, pp. 1-3, 2024

Authors: Honda, Masaya | Shimizu, Fumitaka | Sato, Ryota | Nakamori, Masayuki

Article Type: Review Article

Abstract: Purpose of review: Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group characterized by muscle weakness and skin symptoms and are categorized into six subtypes: dermatomyositis (DM), polymyositis (PM), anti-synthetase syndrome (ASS), immune-mediated myopathy (IMNM), inclusion body myopathy (IBM), and overlap myositis. Myositis-specific autoantibodies were detected for the diagnosis and classification of IIM. This review highlights the pathogenic contributions of the complement system, microangiopathy, and inflammation in IIM. Recent findings: Deposition of complement around capillaries and/or the sarcolemma was observed in muscle biopsy specimens from patients with DM, ASS, and IMNM, suggesting the pathomechanism of complement-dependent muscle and endothelial …cell injury. A recent study using human muscle microvascular endothelial cells showed that Jo-1 antibodies from ASS induce complement-dependent cellular cytotoxicity in vitro . Based on both clinical and pathological observations, antibody- and complement-mediated microangiopathy may contribute to the development of DM and anti-Jo-1 ASS. Juvenile DM is characterized by the loss of capillaries, perivascular inflammation, and small-vessel angiopathies, which may be related to microinfarction and perifascicular atrophy. Several serum biomarkers that reflect the IFN1 signature and microangiopathy are elevated in patients with DM. The pathological observation of myxovirus resistance protein A (MxA), which suggests a type 1 interferon (IFN1) signature in DM, supports the diagnosis and further understanding of the pathomechanism of IIM. A recent report showed that an increase in triggering receptor expressed on myeloid cells (TREM-1) around perimysial blood vessels and muscles in patients with IIM plays a role in triggering inflammation and promoting the migration of inflammatory cells by secreting proinflammatory cytokines, such as tumor necrosis factor α. Summary: The deposition of complement in muscles and capillaries is a characteristic feature of DM, ASS, and IMNM. Microangiopathy plays a pathogenic role in DM, possibly resulting in perifascicular atrophy. Further understanding of the detailed pathomechanism regarding complement, microangiopathy, and inflammation may lead to novel therapeutic approaches for IIM. Show more

DOI: 10.3233/JND-230168

Citation: Journal of Neuromuscular Diseases, vol. 11, no. 1, pp. 5-16, 2024

Authors: Houwen-van Opstal, Saskia L.S. | van der Holst, Menno | Willemsen, Michel A.A.P. | Niks, Erik H. | De Groot, Imelda. J.M. | Cup, Edith H.C.

Article Type: Review Article

Abstract: BACKGROUND: Shortening of the long finger flexors (Flexor Digitorum Profundus, FDPs) in Duchenne Muscular Dystrophy (DMD) causes reduced hand function. Until now, longitudinal studies on the natural course of the shortening of the FDPs are lacking, which impedes recommendations on timing and evaluation of preventive measures. OBJECTIVE: To investigate the longitudinal course of the FDP length during different disease stages focusing on symmetry, timing, and decline of the FDP length. METHODS: A retrospective, longitudinal multicenter study was conducted in the Radboud university medical center and the Leiden university medical center. The FDP outcome was measured using …goniometry and gross motor function was assessed using the Brooke score. Longitudinal mixed model analyses were used to describe the course of the FDP outcome, and to investigate symmetry in both hands. RESULTS: Data on 534 visits of 197 males (age ranged 4–48 years) showed that in the ambulatory stages the FDP outcome was within a normal range. The mean decline in FDP outcome is 3.5 degrees per year, the biggest decline was seen in Brooke 5 (>15 degrees per year). In Brooke 4, 41% of the FDP outcome was < 40 degrees. No significant differences were found between right and left. CONCLUSIONS: This study supports the consideration of preventive measures to delay shortening of the FDPs in DMD patients transitioning to a Brooke scale of 4 or higher. Besides, natural history of FDP outcome has been established, which provides a base to evaluate (preventive) interventions. Show more

Keywords: Duchenne muscular dystrophy, long finger flexors, goniometry, brooke score, longitudinal course

DOI: 10.3233/JND-221653

Citation: Journal of Neuromuscular Diseases, vol. 11, no. 1, pp. 17-23, 2024

Authors: Landfeldt, E. | Aleman, A. | Abner, S. | Zhang, R. | Werner, C. | Tomazos, I. | Lochmüller, H. | Quinlivan, R.M.

Article Type: Systematic Review

Abstract: Background: Despite advances in the medical management of the disease, respiratory involvement remains a significant source of morbidity and mortality in children and adults with Duchenne muscular dystrophy (DMD). Objective: The objective of this systematic literature review was to synthesize and grade published evidence of factors associated with respiratory health and function in DMD. Methods: We searched MEDLINE, Embase, and the Cochrane Library for records of studies published from January 1, 2000 (to ensure relevance to current care practices), up until and including December 31, 2022, reporting evidence of prognostic indicators and predictors of disease progression …in DMD. The quality of evidence (i.e., very low to high) was assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework. Results: The bibliographic search strategy resulted in the inclusion of 29 articles. In total, evidence of 10 factors associated with respiratory health and function in patients with DMD was identified: glucocorticoid exposure (high- to very low-quality evidence), DMD mutations (low-quality evidence), DMD genetic modifiers (low-quality evidence), other pharmacological interventions (i.e., ataluren, eteplirsen, idebenone, and tamoxifen) (moderate- to very low-quality evidence), body mass index and weight (low-quality evidence), and functional ability (low-quality evidence). Conclusions: In conclusion, we identified a total of 10 factors associated with respiratory health in function in DMD, encompassing both pharmacological therapies, genetic mutations and modifiers, and patient clinical characteristics. Yet, more research is needed to further delineate sources of respiratory heterogeneity, in particular the genotype-phenotype association and the impact of novel DMD therapies in a real-world setting. Our synthesis and grading should be helpful to inform clinical practice and future research of this heavily burdened patient population. Show more

Keywords: Muscular dystrophy, Duchenne, lung diseases, pulmonary ventilation, practice guideline, GRADE approach

DOI: 10.3233/JND-230094

Citation: Journal of Neuromuscular Diseases, vol. 11, no. 1, pp. 25-57, 2024

Authors: Jensen, Synnøve M. | Friborg, Oddgeir | Mellgren, Svein Ivar | Müller, Kai Ivar | Bergvik, Svein | Arntzen, Kjell Arne

Article Type: Research Article

Abstract: Background: Limb-girdle muscular dystrophy R9 (LGMDR9) is a chronic progressive hereditary muscle disease, related to the Fukutin Related Protein (FKRP) gene, that may cause major disabilities, cardiomyopathy, and ventilatory failure. Knowledge of how LGMDR9 affects health-related quality of life (HRQoL) is relevant in treatment and care. Objective: To investigate HRQoL in the Norwegian LGMDR9 population over 14 months and relation to fatigue and sleep quality. Methods: Participants (16+ years) of the Norwegian LGMDR9 cohort study completed two HRQoL measures, i.e., Individualized Neuromuscular Quality of Life questionnaire (INQoL) and the 36-item Short Form (SF-36) at baseline, 8, …and 14 months and measures of fatigue and sleep quality at 9 months. Results: HRQoL response rate was 84/90 (75 c.826 C > A homozygotes and nine c.826 C > A compound heterozygotes). Compared to Norwegian normative data, all SF-36 domain scores were impaired (p ≤0.006) except mental health in males (p  = 0.05) and pain scores. During 14 months, perceived muscle weakness and the INQoL index (disease burden) worsened in c.826 C > A homozygotes. Compound heterozygotes reported more dysphagia and physical difficulties than homozygotes and showed a tendency towards worsening in weakness over time but some improvement on the INQoL index. Homozygous females reported generally poorer HRQoL and a higher burden than males. The INQoL index was related to perceived muscle weakness and fatigue, and fatigue to myalgia and mental distress. The prevalence of fatigue and poor sleep was 40% and 49%, respectively. Conclusions: The 14-month follow-up period shows a worsening of perceived weakness and burden in c.826 C > A homozygotes, which can then be expected. The prevalence and impact of fatigue indicate a need for awareness and treatment of fatigue. Myalgia and mental distress are potential targets in the treatment of fatigue, which future studies need to establish. Sleep issues and gender-specific care needs also require attention in LGMDR9. Show more

Keywords: Muscular dystrophies, Limb-girdle, quality of life, sleep quality, fatigue

DOI: 10.3233/JND-221629

Citation: Journal of Neuromuscular Diseases, vol. 11, no. 1, pp. 59-74, 2024

Authors: Sitas, Barbara | Hancevic, Mirea | Bilic, Katarina | Bilic, Hrvoje | Bilic, Ervina

Article Type: Research Article

Abstract: Background: Risdiplam is an orally administered treatment for spinal muscular atrophy which leads to an improvement in motor function as measured by functional motor scales compared with placebo. Although risdiplam has been registered since 2020, real-world data in adults is still scarce. There have been no new safety signals so far, with some results pointing that risdiplam may be effective Objective: The objective was to present real-world data of 31 adult patients with spinal muscular atrophy type 2 and type 3 treated with risdiplam in the Republic of Croatia Methods: Treatment effects were assessed with motor …function tests and patient reported outcome measures, including Individualized Neuromuscular Quality of Life questionnaire, and Jaw Functional Limitation Scale. Side effects, as well as subjective improvements and symptoms, were noted. Results: Majority of patients did not report any side effects. During treatment, we have observed clinically meaningful improvements in some patients, with stabilization of motor functions in the remaining patients. The majority of patients with bulbar function impairment experienced bulbar function improvement, all patients reported an increased quality of life with treatment. An unexpected observed treatment effect was weight gain in a third of all patients with some patients reporting an increase in appetite and subjective improvement in digestion. Conclusions: Risdiplam treatment was well tolerated with subjective and objective positive outcomes registered as measured by functional motor scales and patient-reported outcomes. Since risdiplam is administered orally and acts as a systemic therapy for a multisystemic disorder, effects in systems other than neuromuscular can be expected and should be monitored. Due to systemic nature of the disease patients need multidisciplinary monitoring. Show more

Keywords: Risdiplam, SMA, patient reported outcome measures

DOI: 10.3233/JND-230197

Citation: Journal of Neuromuscular Diseases, vol. 11, no. 1, pp. 75-84, 2024

Authors: Cutrona, Costanza | de Sanctis, Roberto | Coratti, Giorgia | Capasso, Anna | Ricci, Martina | Stanca, Giulia | Carnicella, Sara | Utlulig, Meric | Bersani, Giulia | lazzareschi, Ilaria | Leoni, Chiara | Buonsenso, Danilo | Luciano, Rita | Vento, Giovanni | Finkel, Richard S. | Pane, Marika | Mercuri, Eugenio

Article Type: Research Article

Abstract: Background: The CHOP-INTEND is an established outcome measure used to assess motor function in young and weak SMA patients previously validated in type I infants older than 3 months. Objective: The aim of our study was to assess the maturation of the CHOP-INTEND scores in a group of healthy infants, establishing which items of the scale can be reliably used in individuals younger than 3 months. Methods: This is a prospective observational study. The whole cohort was divided into 5 age groups. Each of the 16 CHOP-INTEND items was analyzed looking at the frequency distribution of …the scores in each age subgroup. An item was considered developmentally appropriate when > 85% of the infants achieved a full score. Results: our study includes 61 assessments collected < 2 weeks, 25 at 2–4 weeks, 20 at 5–8 weeks, 25 at 9–12 weeks and 20 at 13–17 weeks. Eight of the 16 items were developmentally appropriate already in the first week and another by the end of the first month. The remaining 7 items had more variable responses in the first three months and full scores were consistently achieved only after the third month. Conclusions: Our findings suggest that the CHOP-INTEND can be used before the age of 3 months, but the results should be interpreted with caution, considering which items are developmentally appropriate at the time of testing. This will also help to establish whether the changes observed following early treatments are a sign of efficacy or at least partly reflect maturational aspects. Show more

Keywords: CHOP-INTEND, outcome measure, SMA, motor function, maturation, early treatment

DOI: 10.3233/JND-221644

Citation: Journal of Neuromuscular Diseases, vol. 11, no. 1, pp. 85-90, 2024

Authors: Otto, Louise A.M. | Froeling, M. | van Eijk, Ruben P.A. | Wadman, Renske I. | Cuppen, Inge | van der Woude, Danny R. | Bartels, Bart | Asselman, Fay-Lynn | Hendrikse, Jeroen | van der Pol, W. Ludo

Article Type: Research Article

Abstract: Background: Spinal muscular atrophy (SMA) is caused by deficiency of survival motor neuron (SMN) protein. Intrathecal nusinersen treatment increases SMN protein in motor neurons and has been shown to improve motor function in symptomatic children with SMA. Objective: We used quantitative MRI to gain insight in microstructure and fat content of muscle during treatment and to explore its use as biomarker for treatment effect. Methods: We used a quantitative MRI protocol before start of treatment and following the 4th and 6th injection of nusinersen in 8 children with SMA type 2 and 3 during the first …year of treatment. The MR protocol allowed DIXON, T2 mapping and diffusion tensor imaging acquisitions. We also assessed muscle strength and motor function scores. Results: Fat fraction of all thigh muscles with the exception of the m. adductor longus increased in all patients during treatment (+3.2%, p  = 0.02). WaterT2 showed no significant changes over time (–0.7 ms, p  = 0.3). DTI parameters MD and AD demonstrate a significant decrease in the hamstrings towards values observed in healthy muscle. Conclusions: Thigh muscles of children with SMA treated with nusinersen showed ongoing fatty infiltration and possible normalization of thigh muscle microstructure during the first year of nusinersen treatment. Quantitative muscle MRI shows potential as biomarker for the effects of SMA treatment strategies. Show more

Keywords: Muscular atrophy, spinal, magnetic resonance imaging, diffusion tensor imaging, therapeutics

DOI: 10.3233/JND-221671

Citation: Journal of Neuromuscular Diseases, vol. 11, no. 1, pp. 91-101, 2024

Authors: Karazi, Walaa | Coppers, Jacqueline | Maas, Daphne | Cup, Edith | Bloemen, Bart | Voet, Nicole | Groothuis, Jan T. | Pinós, Tomàs | Marti Seves, Ramon | Quinlivan, Ros | Løkken, Nicoline | Vissing, John | Bhai, Salman | Wakelin, Andrew | Reason, Stacey | Voermans, Nicol C.

Article Type: Research Article

Abstract: Background: Glycogen storage disease type 5 (GSD) is an autosomal recessive inherited metabolic myopathy caused by a deficiency of the enzyme muscle glycogen phosphorylase. Individuals with GSD5 experience physical activity intolerance. Objective: This patient-led study aimed to capture the daily life experiences of GSD5, with a focus on adapting to and coping with their physical activity intolerance. Methods: An online survey was composed in close collaboration with patient organizations. It consisted of customized and validated questionnaires on demographics, general health and comorbidities, physical activity, psychosocial well-being and functioning, pain, fatigue and adapting to and coping with …GSD5. Results: One hundred sixty-two participants (16 countries) participated. The majority, n  = 86 (69%) were from the Netherlands, USA or UK. We observed a high rate of misdiagnosis prior to GSD5 diagnosis (49%), surprisingly a relatively high proportion had not been diagnosed by DNA testing which is the gold standard. Being diagnosed had a strong impact on emotional status, daily life activities and important life choices. A large proportion had not received any rehabilitation (41%) nor medical treatment (57%) before diagnosis. Engagement in vigorous and moderate physical activity was reduced. Health related quality of life was low, most likely related to low physical health. The median Fatigue Severity Score was 4.3, indicating moderate to severe fatigue. Participants themselves had found various ways to adapt to and cope with their disability. The adaptations concerned all aspect of their life, including household chores, social and physical activities, and work. In addition to lack of support, participants reported limited availability of information sources. Conclusion: Participants have provided guidance for newly diagnosed people, including the advice to accept one’s limited abilities and maintain an active lifestyle. We conclude that adequate counseling on ways of adapting and coping is expected to increase both health-related quality of life and physical activity. Show more

Keywords: McArdle disease, GSD5, quality of life, adaptations, adjustments, physical activity, international survey

DOI: 10.3233/JND-230027

Citation: Journal of Neuromuscular Diseases, vol. 11, no. 1, pp. 103-116, 2024

Authors: Landfeldt, Erik | Leibrock, Berenike | Hussong, Justine | Thiele, Simone | Abner, Sophia | Walter, Maggie C. | Moehler, Eva | Zemlin, Michael | Dillmann, Ulrich | Flotats-Bastardas, Marina

Article Type: Research Article

Abstract: Background: Spinal muscular atrophy (SMA) is a rare, severely debilitating neuromuscular disease characterized by a wide spectrum of progressive muscular atrophy and weakness. Objectives: The objective of this pilot study was to estimate self-assessed health-related quality of life (HRQoL) of children with SMA. Methods: Children with SMA were recruited via the German national TREAT-NMD SMA patient registry and asked to self-complete the following rating-scales: KIDSCREEN-27, KINDL, the PedsQL 3.0 Neuromuscular Module (PedsQL 3.0 NMM), EQ-5D-5L, and the Health Utilities Index (HUI). Estimates were stratified by current best motor function of the lower limb and trunk (i.e., …non-sitter, sitter, and walker) and SMA type (i.e., type I, II, and III). Results: In total, 17 children with SMA (mean age: 9.88 years, SD: 4.33 years, range: 5–16 years; 59% female) participated in the study. Across examined strata, the mean KIDSCREEN-27 total score was estimated at between 48.24 and 83.81; the mean KINDL total score at between 60.42 and 76.73; the mean PedsQL 3.0 NMM total score at between 58.00 and 83.83; the mean EQ-5D-5L utility at between 0.31 and 0.99; and the mean HUI-derived utility at between –0.02 and 0.96. Conclusions: The results from this pilot study show that German children with SMA, despite significant physical disability, have surprisingly good HRQoL as assessed using KIDSCREEN-27. Yet, many reside in health states associated with low utility. The disease burden was generally higher among non-sitters compared with walkers, and SMA type I compared with type III, but more research is needed to further delineate this variability. Our preliminary findings contribute to the understanding of HRQoL in pediatric patients with SMA and should be helpful to inform the design of future studies of this patient population. Show more

Keywords: Quality of Life, muscular atrophy, spinal, burden of illness, activities of daily living, therapy

DOI: 10.3233/JND-230071

Citation: Journal of Neuromuscular Diseases, vol. 11, no. 1, pp. 117-128, 2024

Authors: Meyer, Alayne P. | Connolly, Anne M. | Vannatta, Kathryn | Hacker, Natasha | Hatfield, Andrea | Decipeda, Abigail | Parker, Patricia | Willoughby, Ava | Waldrop, Megan A.

Article Type: Research Article

Abstract: Background: Spinal muscular atrophy (SMA) is a genetic neurodegenerative disorder with onset predominantly in infants and children. In recent years, newborn screening and three treatments, including gene replacement therapy (Onasemnogene abeparvovec-xioi), have become available in the United States, aiding in the diagnosis and treatment of children with SMA. Objective: To evaluate parents’ experiences with newborn screening and gene replacement therapy and to explore best practices for positive newborn screen disclosure and counseling of families. Methods: We conducted semi-structured interviews (n  = 32) and online surveys (n  = 79) of parents whose children were diagnosed with …SMA (on newborn screening or symptomatically) and treated with gene replacement therapy. Results: Gene replacement therapy was most parents’ first treatment choice, although concerns regarding long term efficacy (65%) and safety (51%) were common. Information provided during the newborn screening disclosure was quite variable. Only 34% of parents reported the information provided was sufficient and expressed need for more information about treatment. Although many parents experienced denial of the diagnosis at initial disclosure, 94% were in favor of inclusion of SMA on newborn screening. Parents were almost universally anxious following diagnosis and over half remained anxious at the time of study participation with uncertainty of the future being a key concern. Many parents had difficulty processing information provided during their first clinic appointment due to its complexity and their emotional state at the time. Conclusions: Utilizing this data, we provide a recommendation for the information provided in newborn screening disclosure, propose adjustments to education and counseling during the first clinic visit, and bring awareness of parents’ mental health difficulties. Show more

Keywords: Spinal muscular atrophy, neonatal screening, genetic therapy, Onasemnogene abeparvovec-xioi

DOI: 10.3233/JND-230082

Citation: Journal of Neuromuscular Diseases, vol. 11, no. 1, pp. 129-142, 2024

Authors: Kölbel, Heike | Kopka, Marius | Modler, Laura | Blaschek, Astrid | Schara-Schmidt, Ulrike | Vill, Katharina | Schwartz, Oliver | Müller-Felber, Wolfgang

Article Type: Research Article

Abstract: Objective: Numerous studies have consistently found that reduced SMN protein expression does not severely affect cognitive function in SMA patients. However, the average intelligence quotient of SMA patients has ranged above to below average in different studies. The cognitive development of SMA patients identified through newborn screening remains largely unknown. Methods: 40 of 47 eligible SMA patients (23 females/17 males) from 39 families identified through newborn screening between January 2018 and December 2020 underwent developmental testing using Bayley III (BSID) after the 2 years of age. The mean age was 29.25 months (23–42 months). 17 patients had 2, …11 patients had 3 and 12 patients had ≥4 copies of SMN2. Results: cognitive scale: mean 94.55 (SD 24.01); language scale: mean 86.09 (SD 26.41); motor scale: 81.28 (SD 28.07). Overall, the cognitive scales show that 14 children were below average, 20 children were average and 6 children were above average. 10/14 children with below average scores had 2 SMN2 copies. The post-hoc pairwise comparisons showed that the cognition main scale was significantly more sensitive to the number of SMN2 copies than the motor main scale of the BSID (MΔ = 10.27, p  = 0.014). There is also evidence that cognition scored higher than the language main scale (MΔ = 7.11, p  = 0.090). Conclusion: The impaired cognitive development of SMA children with 2 SMN2 copies, despite early initiation of therapy, underscores the critical role of the SMN protein in the early stages of brain development. Show more

Keywords: Cognitive development, SMN protein, newborn screening, spinal muscular atrophy, BSID-III

DOI: 10.3233/JND-230136

Citation: Journal of Neuromuscular Diseases, vol. 11, no. 1, pp. 143-151, 2024

Authors: Stimpson, Georgia | Ridout, Deborah | Wolfe, Amy | Milev, Evelin | O’Reilly, Emer | Manzur, Adnan | Sarkozy, Anna | Muntoni, Francesco | Cole, Tim J. | Baranello, Giovanni

Article Type: Research Article

Abstract: Background Boys with Duchenne Muscular Dystrophy (DMD) display heterogeneous motor function trajectory in clinics, which represents a significant obstacle to monitoring. Objective: In this paper, we present the UK centiles for the North Star Ambulatory Assessment (NSAA), the 10 m walk/run time (10MWR) and velocity (10MWRV), and the rise from floor time (RFF) and velocity (RFFV) created from a cohort of glucocorticoid treated DMD boys between the age of 5 and 16 years. Methods: Participants were included from the UK NorthStar registry if they had initiated steroids (primarily deflazacorts/prednisolone, intermittent/daily) and were not enrolled …in an interventional trial. Assessments were included if the participant had a complete NSAA, the timed tests had been completed or the corresponding items were 0, or the participant was recorded as non-ambulant, in which case the NSAA was assumed 0. Results: We analysed 3987 assessments of the NSAA collected from 826 participants. Of these, 1080, 1849 and 1199 were imputed as 0 for the NSAA, RFFV and 10MWRV respectively. The 10th, 25th, 50th, 75th and 90th centiles were presented. The NSAA centiles showed a peak score of 14, 20, 26, 30 and 32 respectively, with loss of ambulation at 10.7, 12.2 and 14.3 years for the 25th, 50th and 75th centiles, respectively. The centiles showed loss of rise from floor at 8.6, 10.1 and 11.9 years and a loss of 10MWR of 0 at 8.9, 10.3 and 13.8 years for the 25th, 50th and 75th centiles, respectively. The centiles were pairwise less correlated than the raw scores, suggesting an increased ability to detect variability in the DMD cohort. Conclusions: The NSAA, 10MWR and RFF centiles may provide insights for clinical monitoring of DMD boys, particularly in late ambulatory participants who are uniformly declining. Future work will validate the centiles in national and international natural history cohorts. Show more

Keywords: Duchenne muscular dystrophy, NorthStar ambulatory assessment, centiles, glucocorticoids, rise from floor, 10 meter walk/run

DOI: 10.3233/JND-230159

Citation: Journal of Neuromuscular Diseases, vol. 11, no. 1, pp. 153-166, 2024

Authors: Pfrimmer, Charlotte | Smitka, Martin | Muschol, Nicole | Husain, Ralf A. | Huemer, Martina | Hennermann, Julia B. | Schuler, Rahel | Hahn, Andreas

Article Type: Research Article

Abstract: Background: Enzyme replacement therapy (ERT) with recombinant human alglucosidase alfa (rhGAA) was approved in Europe in 2006. Nevertheless, data on the long-term outcome of infantile onset Pompe disease (IOPD) patients at school age is still limited. Objective: We analyzed in detail cardiac, respiratory, motor, and cognitive function of 15 German-speaking patients aged 7 and older who started ERT at a median age of 5 months. Results: Starting dose was 20 mg/kg biweekly in 12 patients, 20 mg/kg weekly in 2, and 40 mg/kg weekly in one patient. CRIM-status was positive in 13 patients (86.7%) and negative …or unknown in one patient each (6.7%). Three patients (20%) received immunomodulation. Median age at last assessment was 9.1 (7.0–19.5) years. At last follow-up 1 patient (6.7%) had mild cardiac hypertrophy, 6 (42.9%) had cardiac arrhythmias, and 7 (46.7%) required assisted ventilation. Seven patients (46.7%) achieved the ability to walk independently and 5 (33.3%) were still ambulatory at last follow-up. Six patients (40%) were able to sit without support, while the remaining 4 (26.7%) were tetraplegic. Eleven patients underwent cognitive testing (Culture Fair Intelligence Test), while 4 were unable to meet the requirements for cognitive testing. Intelligence quotients (IQs) ranged from normal (IQ 117, 102, 96, 94) in 4 patients (36.4%) to mild developmental delay (IQ 81) in one patient (9.1%) to intellectual disability (IQ 69, 63, 61, 3x <55) in 6 patients (54.5%). White matter abnormalities were present in 10 out of 12 cerebral MRIs from 7 patients. Conclusion: Substantial motor, cardiac, respiratory, and cognitive deficits are frequent in IOPD long-term survivors who started ERT before 2016. The findings of this study can be valuable as comparative data when evaluating the impact of newer treatment strategies including higher enzyme dosage, immunomodulation, modified enzymes, or early start of treatment following newborn screening. Show more

Keywords: Infantile onset Pompe disease, prognosis, long-term outcome

DOI: 10.3233/JND-230164

Citation: Journal of Neuromuscular Diseases, vol. 11, no. 1, pp. 167-177, 2024

Authors: Saunders, Charlie | Longman, Cheryl | Gorman, Grainne | James, Kelly | Oliwa, Agata | Petty, Richard | Snadden, Lesley | Farrugia, Maria Elena

Article Type: Research Article

Abstract: Background: The m.3243A>G variant is the commonest mitochondrial (mt) DNA pathogenic variant and a frequent cause of mitochondrial disease. Individuals present with a variety of clinical manifestations from diabetes to neurological events resembling strokes. Due to this, patients are commonly cared for by a multidisciplinary team. Objectives: This project aimed to identify patients with confirmed mt.3243A>G-related mitochondrial disease attending the Muscle Clinic at Queen Elizabeth University Hospital in Glasgow. We explored potential correlates between clinical phenotypes and mtDNA heteroplasmy levels, HbA1c levels, body mass index, and specific clinical manifestations. We investigated if there were discrepancies between non-neurological speciality …labelling in clinical records and individuals’ phenotypes. Methods: Data were gathered from the West of Scotland electronic records. Phenotypes were ascertained by a clinician with expertise in mitochondrial disorders. Statistical analyses were applied to study relationships between tissue heteroplasmy, HbA1c and clinical phenotypes including body mass index (BMI). Results: Forty-six individuals were identified from 31 unrelated pedigrees. Maternally inherited diabetes and deafness was the prominent syndromic phenotype (48%). A significant association was found between overall number of symptoms and bowel dysmotility (p  < 0.01). HbA1c was investigated as a predictor of severity with potential association seen. Although used widely as a prognosticator, neither corrected blood nor urine mtDNA heteroplasmy levels were associated with increased number of symptoms. In 74.1% of records, syndromic phenotypes were incorrectly used by non-neurological specialities. Conclusions: This m.3243 A > G patient cohort present with marked clinical heterogeneity. Urine and blood heteroplasmy levels are not reliable predictors of disease severity. HbA1c may be a novel predictor of disease severity with further research required to investigate this association. We infer that prognosis may be worse in patients with low BMIs and in those with bowel dysmotility. These results underscore a multidisciplinary approach and highlight a problem with inaccurate use of the existing nomenclature. Show more

Keywords: Epidemiology, mitochondrial conditions, mitochondrial DNA, m.3243A>G, multidisciplinary team

DOI: 10.3233/JND-230166

Citation: Journal of Neuromuscular Diseases, vol. 11, no. 1, pp. 179-189, 2024

Authors: Kulsirichawaroj, Pimchanok | Suksangkharn, Yanin | Nam, Da Eun | Pho-iam, Theeraphong | Limwongse, Chanin | Chung, Ki Wha | Sanmaneechai, Oranee | Zuchner, Stephan L. | Choi, Byung-Ok

Article Type: Research Article

Abstract: Background: Inherited peripheral neuropathy presents a diagnostic and therapeutic challenge due to its association with mutations in over 100 genes. This condition leads to long-term disability and poses a substantial healthcare burden on society. Objective: This study aimed to investigate the distribution of genes and establish the genotype-phenotype correlations, focusing on pediatric-onset cases. Methods: Exome sequencing and other analytical techniques were employed to identify pathogenic variants, including duplication analysis of the PMP22 gene. Each patient underwent physical examination and electrophysiological studies. Genotypes were correlated with phenotypic features, such as age at disease onset and ulnar …motor nerve conduction velocity. Results: We identified 35 patients with pediatric-onset inherited peripheral neuropathy. Pathogenic or likely pathogenic variants were confirmed in 24 out of 35 (68.6%) patients, with 4 of these variants being novel. A confirmed molecular diagnosis was achieved in 90.9% (10/11) of patients with demyelinating Charcot-Marie-Tooth disease (CMT) and 56.3% (9/16) of patients with axonal CMT. Among patients with infantile-onset CMT (≤2 years), the most common causative genes were MFN2 and NEFL , while GDAP1 and MFN2 were frequent causes among patients with childhood- or adolescent-onset CMT (3–9 years). Conclusions: The MFN2 gene was the most commonly implicated gene, and the axonal type was predominant in this cohort of Thai patients with pediatric-onset inherited peripheral neuropathy. Show more

Keywords: Pediatric-onset, Inherited peripheral neuropathy, Charcot-Marie-Tooth disease, Genotype-phenotype correlations

DOI: 10.3233/JND-230174

Citation: Journal of Neuromuscular Diseases, vol. 11, no. 1, pp. 191-199, 2024

Authors: Clemens, Paula R. | Gordish-Dressman, Heather | Niizawa, Gabriela | Gorni, Ksenija | Guglieri, Michela | Connolly, Anne M. | Wicklund, Matthew | Bertorini, Tulio | Mah, Jean | Thangarajh, Mathula | Smith, Edward C. | Kuntz, Nancy L. | McDonald, Craig M. | Henricson, Erik | Upadhyayula, S | Byrne, Barry | Manousakis, Georgios | Harper, Amy | Iannaccone, Susan | Dang, Utkarsh J.

Article Type: Research Article

Abstract: Background: Becker muscular dystrophy is an X-linked, genetic disorder causing progressive degeneration of skeletal and cardiac muscle, with a widely variable phenotype. Objective: A 3-year, longitudinal, prospective dataset contributed by patients with confirmed Becker muscular dystrophy was analyzed to characterize the natural history of this disorder. A better understanding of the natural history is crucial to rigorous therapeutic trials. Methods: A cohort of 83 patients with Becker muscular dystrophy (5–75 years at baseline) were followed for up to 3 years with annual assessments. Muscle and pulmonary function outcomes were analyzed herein. Age-stratified statistical analysis and modeling …were conducted to analyze cross-sectional data, time-to-event data, and longitudinal data to characterize these clinical outcomes. Results: Deletion mutations of dystrophin exons 45–47 or 45–48 were most common. Subgroup analysis showed greater pairwise association between motor outcomes at baseline than association between these outcomes and age. Stronger correlations between outcomes for adults than for those under 18 years were also observed. Using cross-sectional binning analysis, a ceiling effect was seen for North Star Ambulatory Assessment but not for other functional outcomes. Longitudinal analysis showed a decline in percentage predicted forced vital capacity over the life span. There was relative stability or improved median function for motor functional outcomes through childhood and adolescence and decreasing function with age thereafter. Conclusions: There is variable progression of outcomes resulting in significant heterogeneity of the clinical phenotype of Becker muscular dystrophy. Disease progression is largely manifest in adulthood. There are implications for clinical trial design revealed by this longitudinal analysis of a Becker natural history dataset. Show more

Keywords: Muscular dystrophies, dystrophin, natural history, muscle, skeletal

DOI: 10.3233/JND-230178

Citation: Journal of Neuromuscular Diseases, vol. 11, no. 1, pp. 201-212, 2024

Authors: Frongia, Ivana | Spagnoli, Carlotta | Rizzi, Susanna | Frattini, Daniele | Leon, Alberta | Caraffi, Stefano Giuseppe | Pollazzon, Marzia | Garavelli, Livia | Pisani, Francesco | Fusco, Carlo

Article Type: Short Communication

Abstract: Activating Signal Cointegrator 1 complex (ASC-1 complex) is a ribonucleoprotein tetramer participating in transcriptional coactivation and RNA processing, consisting of four subunits: ASCC1-ASCC3 and ASC-1. Pathogenic variants in the TRIP4 and ASCC1 genes, encoding the ASC-1 and ASCC1 subunits, were recently described in congenital myopathic conditions without signs of motor neuron involvement, and Spinal Muscular Atrophy-like (SMA-like) phenotype with prenatal bone fractures. We present a novel pathogenic TRIP4 variant in two siblings with severe phenotype and mixed sensory-motor polyneuropathy. The reviewed phenotypic spectrum is broad, but sensory-motor polyneuropathy is so-far unreported. We thus expand ASC-1 related myopathy …phenotype. Show more

Keywords: TRIP4, neuropathy, ASC-1, myopathy, hypotonia

DOI: 10.3233/JND-230110

Citation: Journal of Neuromuscular Diseases, vol. 11, no. 1, pp. 213-219, 2024

Authors: Nishadham, Vikas | Santhoshkumar, Rashmi | Nashi, Saraswati | Vengalil, Seena | Bardhan, Mainak | Polavarapu, Kiran | Sanka, Sai Bhargava | Anjanappa, Ram Murthy | Kulanthaivelu, Karthik | Saini, Jitender | Chickabasaviah, Yasha T. | Nalini, Atchayaram

Article Type: Case Report

Abstract: Charcot-Marie-Tooth disease 4H(CMT4H) is an autosomal recessive demyelinating form of CMT caused by FGD4/FRABIN mutations. CMT4H is characterized by early onset and slowly progressing motor and sensory deficits in the distal extremities, along with foot deformities. We describe a patient with CMT4H who presented with rapidly progressing flaccid quadriparesis during the postpartum period, which improved significantly with steroid therapy. Magnetic resonance imaging and ultrasonography demonstrated considerable nerve thickening with increased cross-sectional area in the peripheral nerves. A nerve biopsy revealed significant demyelination and myelin outfolding. This is the first report of an Indian patient with a novel homozygous nonsense …c.1672C>T (p.Arg558Ter) mutation in the FGD4 gene, expanding the mutational and phenotypic spectrum of this disease. Show more

Keywords: Charcot-Marie-Tooth disease type 4H (CMT4H), FGD4 , Indian, novel homozygous mutation, histopathology

DOI: 10.3233/JND-230042

Citation: Journal of Neuromuscular Diseases, vol. 11, no. 1, pp. 221-232, 2024

Authors: Phung, Kim | Crabtree, Nicola | Connolly, Anne M. | Furlong, Pat | Hoffman, Eric P. | Jackowski, Stefan A. | Jayash, Soher Nagi | Johnson, Alex | Koujok, Khaldoun | Munns, Craig F. | Niks, Erik | Rauch, Frank | Schrader, Rachel | Turner, Cathy | Vroom, Elizabeth | Weber, David R. | Wong, Brenda L. | Guglieri, Michela | Ward, Leanne M. | Wong, Sze Choong

Article Type: Meeting Report

Keywords: Bisphosphonates, bone density, glucocorticoid, vertebral fracture

DOI: 10.3233/JND-230176

Citation: Journal of Neuromuscular Diseases, vol. 11, no. 1, pp. 233-252, 2024